The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Open accessAbstract
Introduction Human epidermal growth factor receptor 2 gene (HER2 [also known as ERBB2]) alterations have been identified as oncogenic drivers and potential therapeutic targets in lung cancers. The molecular associations of HER2 gene amplification, mutation, and HER2 protein overexpression in lung cancers have not been distinctly defined. To explore these associations, Memorial Sloan Kettering Cancer Center and the University of Colorado combined their data on HER2 alterations in lung cancers.Methods Tumor specimens from 175 patients with lung adenocarcinomas and no prior targeted therapy were evaluated for the presence of HER2 amplification and mutation and HER2 protein overexpression. Amplification was assessed by fluorescence in situ hybridization (FISH) and defined as an HER2-to-chromosome enumeration probe 17 ratio of at least 2.0. Mutation was assessed by fragment analysis, mass spectrometry genotyping, and Sanger sequencing. Overexpression was assessed by immunohistochemical (IHC) staining. The frequencies of HER2 amplification and mutation and HER2 overexpression were calculated and their overlap examined.Results HER2 amplification was detected by FISH in 5 of 175 cases (3%). HER2 mutation was detected in 4 of 148 specimens (3%), including three identical 12-base pair insertions (p.A775_G776insYVMA) and a 9-base pair insertion, all in exon 20. None of the HER2-mutant cases was amplified. HER2 overexpression (2+ or 3+) on IHC staining was not detected in the 25 specimens available for testing, and negative IHC staining correlated with the negative results according to FISH.Conclusions HER2 mutations are not associated with HER2 amplification, thus suggesting a distinct entity and therapeutic target. HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ten ERBB2 mutations were detected, including 5 exon 20 insertions shown to confer sensitivity to ERBB2-targeted therapies (36).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0912 · Cited by 505
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Gatzemeier, U., Groth, G., Butts, C. A., van Zandwijk, N., Shepherd, F. A., Ardizzoni, A., Barton, C. M., Ghahramani, P., & Hirsh, V. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh031 · Cited by 388
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Grève, J. D., Teugels, E., Geers, C., Decoster, L., Galdermans, D., Mey, J. D., Everaert, H., Umelo, I. A., Veld, P. I. '., & Schallier, D. C. C. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.008 · Cited by 272
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
Hirsch, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Barón, A. E., & Bunn, P. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600286 · Cited by 253
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–289 of 289
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan
Neupane, N., Thapa, S., Bhattarai, A., Ahuja, K., Schlam, I. M., Mittal, A., Tolaney, S. M., & Tarantino, P. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01469-3 · Cited by 7
Time to tackle the blood‐brain barrier in HER2‐mutant lung cancer
Lin, J. J., & Gainor, J. F. (2019) · Cancer · doi:10.1002/cncr.32460 · Cited by 5
Peng, S., Cai, J., & Bao, S. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12470 · Cited by 5
Kıvrak, H., Özakıncı, H., Karasoy, D., & Sak, S. D. (2021) · Balkan Medical Journal · doi:10.5152/balkanmedj.2021.21144 · Cited by 5
Sunpaweravong, P., Thongwatchara, P., Chotipanvithayakul, R., Sangkhathat, S., & Thongsuksai, P. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2705 · Cited by 5
Real-world characteristics and outcomes of ERBB2- mutant NSCLC in Latin American patients (CLICaP)
Saldanha, E. F., de Lima, V. C. C., Fares, A. F., Corassa, M. P., Gil-Santana, L., Arrieta, O. G., Soler, J., Chamorro, D. F., Rodrigues, J., Freitas, H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae347 · Cited by 4
Antibody–drug conjugates in lung cancer: current landscape and future perspectives
Chen, X., & Zhou, C. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001200 · Cited by 4
Yeo, M., Kim, S., Yoo, H. J., Suh, K., & Kim, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236963 · Cited by 4
Kumarasinghe, P. M., Houghton, D., Allanson, B. M., & Price, T. J. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.05.004 · Cited by 4
Assessment of HER2 status of carcinomas of various localizations
Vtorushin, S. V., Krakhmal, N. V., Эдуардовна, З. Л., Кузнецова, О. А., Moskvina, L. V., & Франк, Г. А. (2023) · Russian Journal of Archive of Pathology · doi:10.17116/patol20238506131 · Cited by 5
Pan, X., & Zhou, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1397238 · Cited by 4
Verma, S., Chapman, A., Pickard, L.-A., Porplycia, D., McConkey, H., Jarosz, P., Sinfield, J., Lauzon-Young, C., Cecchini, M. J., Howlett, C. J., et al. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00265 · Cited by 7
Alternative splicing of HER2: a novel mediator of EGFR TKI resistance
Yochum, Z. A., & Villaruz, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-618 · Cited by 4
Molekularpathologische Diagnostik an zytologischen Präparaten
Fassunke, J., Ball, M., & Engels, M. (2020) · Der Pathologe · doi:10.1007/s00292-019-00733-3 · Cited by 4
Finding chinks in the osimertinib resistance armor
Leal, J. L., Solomon, B., & John, T. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-579 · Cited by 3
Metro, G., Baglivo, S., Moretti, R., Bellezza, G., Sidoni, A., & Roila, F. (2020) · Oncology and Therapy · doi:10.1007/s40487-020-00121-5 · Cited by 4
In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC
Shrestha, L., Singh, S. S., Parajuli, P., Dahal, A., Mattheolabakis, G., Meyer, S. A., Bhattacharjee, J., & Jois, S. D. S. (2020) · Journal of Cancer · doi:10.7150/jca.46320 · Cited by 4
Sun, C., Xu, Y., Wang, X., Guo, Y., Qiu, S., Shao, G., Yang, Z., Liu, Y., Zhang, P., & Ma, K. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000995 · Cited by 4
Metro, G., Giglio, A. D., Ricciuti, B., Siringo, M., Marinelli, D., Gelibter, A. J., Pecci, F., Berardi, R., Cantini, L., Federico, A. D., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-9 · Cited by 4
Sun, Y., Wei, L.-M., & Qian, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2506302 · Cited by 3
Liu, X., Cao, Y., Li, Y., & Duan, X. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2020.02.14 · Cited by 3
Bao, R., Ng, A. K. Y., Sasaki, M. M., Selvan, M. E., Katti, A., Lee, H., Huang, L., Skol, A. D., Lavarino, C. E., Salvador, H., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0094 · Cited by 4
Grell, P., Bořilová, S., Bílek, O., & Kišš, I. (2021) · Klinicka onkologie · doi:10.48095/ccko2021s20 · Cited by 3
Shiraishi, A., Oh‐hara, T., Takahashi, Y., Uchibori, K., Nishio, M., & Katayama, R. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150255 · Cited by 3
miR-497-5p Expression and Biological Activity in Gastric Cancer
Chen, X., Zhou, L., Han, Y., Lin, S., Zhou, L., Wang, W., Zhang, W. Y., Xuan, S., Yu, J., & Zheng, W. (2024) · Journal of Cancer · doi:10.7150/jca.90087 · Cited by 3
HER2 induces cell scattering and invasion through ∆Np63α and E-cadherin
Shan, L., Tang, X., Ye, T., & Xiang, W. (2022) · Biochemistry and Cell Biology · doi:10.1139/bcb-2022-0099 · Cited by 3
Jónsdóttir, G., Smith, M., Wood, S., Hejleh, T. A., & Furqan, M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-596 · Cited by 3
Future of lung cancer treatment
Petruzelka, L. B., Špaček, J., & Křížová, Ľ. (2021) · Klinicka onkologie · doi:10.48095/ccko2021s71 · Cited by 3
Uchida, S., & Sugino, T. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090468 · Cited by 2
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls
Russo, G., Scimone, C., Palumbo, L., Roscigno, G., Sarracino, C., Tomaiuolo, I., Pisapia, P., Pepe, F., Rocco, D., Gridelli, C., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104748 · Cited by 2
Robert, S. M., Toth, A. J., Lev, S., Bowden, S. G., Yu, Y., Imber, B. S., Boire, A. A., Drago, J. Z., Modi, S., & Moss, N. S. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05083-0 · Cited by 2
Ichimata, M., Kagawa, Y., Toshima, A., Igase, M., & Mizuno, T. (2025) · Veterinary and Comparative Oncology · doi:10.1111/vco.70020 · Cited by 2
Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC
Chugh, B., Dave, R., Ramesh, A., Khutale, G. V., Hariramani, K., Andhari, S. S., D’Souza, A., Iyer, S., Basavalingegowda, M., Halder, S., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100332 · Cited by 2
Wang, H., Sun, W., Wang, C., Yang, X., Chi, K., Liu, X., Huang, X., Zhou, L., & Lin, D. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.11.015 · Cited by 2
McMahon, D. J., John, A., Kalofonou, F., Amin, N., Sarker, S., Vick, J., Yousaf, N., Tokaca, N., Robertus, J., MacMahon, S., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.100960 · Cited by 2
Evolving treatment strategies for HER2-altered non–small-cell lung cancer: the rise of TKIs and ADCs
Ballı, S., Başoğlu, T., & Ozdogan, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771869 · Cited by 2
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
Li, H., Li, X., Lan, S., Zuo, X., Du, T., Liu, Y., Zhang, C., Zhu, J., & Cheng, Y. (2022) · Tumori Journal · doi:10.1177/03008916221101426 · Cited by 2
Gong, K., Yang, Y., Huang, H., Kuang, X., & Yang, X. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2375 · Cited by 2
An expanding role for osimertinib for the treatment of ErbB family driven NSCLC
Faber, A. C., & Burns, T. F. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.08.10 · Cited by 2
Ruan, M., Chang, C., Sun, J., Liu, L., Wang, L., Lei, B., Yan, H., Zhang, H., Xie, W., & Wang, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05218-8 · Cited by 1
Hou, Y., Xue, X., Zhang, Z., Mai, D., Luo, W., Zhou, M., Liu, Z., & Huang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14125-9 · Cited by 1
Cytoskeletal remodeling via CAMSAP3 downregulation drives resistance to osimertinib in NSCLC cells
Yang, F., Wang, Z., Han, X., Zhong, J., Hou, Z., Bian, S., Long, J., & Liu, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08299-0 · Cited by 2
Tanvetyanon, T., Chen, D.-T., & Gray, J. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093481 · Cited by 1
Goto, K., Hayashi, H., Maruti, S. S., Zettl, H., Mittal, L., Pathak, S., & Le, X. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01213-4 · Cited by 1
Debieuvre, D., Macouillard, P., Quantin, X., BERKTAŞ, M., Girard, N., Audigier-Valette, C., Filleron, T., Musilli, S., Bosquet, L., & Pérol, M. (2026) · Cancer Medicine · doi:10.1002/cam4.71975 · Cited by 1
ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers
Shreenivas, A. V., Elliott, A., Corbiere, T. F., Chen, H.-Z., George, B., Kamgar, M., Chakrabarti, S., Desai, A. P., Bracken-Clarke, D. M., Xue, E., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.107772 · Cited by 1
Chang, L., & Shih, J. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00114 · Cited by 1
Castillon, M., Bourhis, A., Quintin‐Roué, I., & Uguen, A. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000879 · Cited by 1
Toward Identifying Key Gene Group in the Occurrence and Development of Lung Adenocarcinoma
Gu, M., Zhao, T.-F., Liu, W., Wu, X.-K., & Yang, L. (2021) · IEEE Access · doi:10.1109/access.2021.3054162 · Cited by 1
Berchem, G., & Peters, S. (2024) · Springer eBooks · doi:10.1007/978-3-030-93702-7_3-1 · Cited by 1
Pineda, C. M., O’Loughlin, L., Benjamin, H. L., Rangachari, D., Viray, H., Widick, P. C., Guan, Z., Beattie, J., Swenson, K. E., Parikh, M. S., et al. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2025-210095 · Cited by 1
Isaacs, J. M., & Clarke, J. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-800684-9.00006-x · Cited by 1
HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules
Yin, J., Huo, S., Chen, Z., Shi, Y., Sui, Q., Wang, Q., Xu, J., & Jiang, W. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03955-3 · Cited by 1
Cooper, A. J., & Riely, G. J. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01900 · Cited by 1
Immunohistochemistry of Lung Cancer Biomarkers
Beasley, M. B. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62941-4_9
Mutations as Predictive Biomarkers for Adenocarcinoma
Mahadevan, N. R., & Sholl, L. M. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62941-4_11
Карабина, Е. В., Lubchenko, L. N., & Давыдов, М. М. (2018) · Advances in molecular oncology · doi:10.17650/2313-805x-2018-5-3-17-24
Bulbul, A., Leal, A., & Husain, H. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_6
Molekularpathologische Diagnostik an zytologischen Präparaten
Fassunke, J., Ball, M., & Engels, M. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-020-00333-5
Tao, C., Chen, M.-Y., Tseng, C.-M., Lapke, N., Chen, S., & Tan, K. T. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/9072173
Карабина, Е. В., Lubchenko, L. N., & Garunov, A. N. (2018) · Journal of Modern Oncology · doi:10.26442/1815-1434_2018.3.10-18
Yochum, Z. A., & Stabile, L. P. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-617
Progress in anti-HER2 targeted therapy of metastatic lung cancer
Xiao, X. M., & Jia, Y. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202127103074
Thérapies ciblées et carcinomes non à petites cellules : nouveautés
Stauber, R., Louis Gro, S., Nguyen‐Ngoc, T., Mederos, N., Bouchaab, H., Peters, S., & Abdelhamid, K. (2022) · JMIG · doi:10.53738/revmed.2022.18.782.970
Chang, J. C., Offin, M. D., Falcon, C. J., Brown, D. N., Houck-Loomis, B. R., Meng, F., Rudneva, V. A., Won, H. H., Amir, S., Montecalvo, J., et al. (2023) · doi:10.1158/1078-0432.c.6530487.v1
Bao, R., Ng, A. K. Y., Sasaki, M. M., Selvan, M. E., Katti, A., Lee, H., Huang, L., Skol, A. D., Lavarino, C. E., Salvador, H., et al. (2023) · doi:10.1158/1940-6207.c.6547366.v1
Molecular Carcinogenesis of Lung Cancer
Akyürek, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-22483-6_59-1
Su, Y., Huo, T., Wang, Y., & Li, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03703-1
DESTINY of Immunotherapy in Patients With HER2 Mutant Lung Cancer: Case Report
Landi, L. M., Fusco, F., Melis, E., Buglioni, S., Visca, P., Minuti, G., & Cappuzzo, F. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100818
Hájková, N., Pavlíčková, K., Dvořák, J., Hojny, J., Krkavcová, E., Waldauf, P., Dundr, P., Drösslerová, M., Švajdler, M., Fabián, P., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04285-1
Molecular Pathology of Lung Tumors
Popper, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-91697-7_19
Lin, J.-X., Yin, K., Yan, L.-X., Zhu, Y., Xu, B.-F., Sun, Y.-L., Wu, Y.-L., & Tu, H.-Y. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108912
Cappuzzo, F., Zhang, L., Dunton, K., Dennis, N., Nouveau, P. L., Nevière, A., & Gauthier, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1708245
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153
Scurtu, G. A., Sala, D. T., Jung, I., Bara, T., Neagoe, R. M., Fülöp, Z. Z., & Gurzu, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114673 · Cited by 2
Pourfaraji, S. M., Abdollahi, A., Shirmard, F. O., Ghalehtaki, R., & Salarvand, S. (2026) · Cancer Reports · doi:10.1002/cnr2.70612
Elantably, D., Meerzaman, I., Hou, A. Y., Abdelhakeem, A., & Lou, Y. (2026) · Cancers · doi:10.3390/cancers18132121
HER2 assessment in urothelial carcinoma: standardization challenges and the path forward
Xie, P. Y., Wang, Y., Lu, L., Chen, J., Wei, J., Huang, Y., Guo, C., Li, J., Yan, X., Guo, J., et al. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10353-y
Zullo, L., & Remón, J. (2026) · Cancers · doi:10.3390/cancers18142334
Bittar, H. E. T., & Dacic, S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000839
Janne, P. A., Zhou, C., Smit, E. F., Felip, E., Blumenschein, G., Goto, K., William, W. N., Abe, C., Lin, J., Cheng, C.-Y., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2724696
Innovative therapies for HER2-altered non-small cell lung cancer: A narrative review
Arrieta, O. G., Caballé‐Perez, E., Cabrera-Miranda, L. A., Cardona, A. F., Davila-Dupont, D., Velasco-Córdoba, M., & Treviño, L. A. C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105619
Yoshimura, A., Yoshida, J., Takumi, C., & Takayama, K. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01263-8
Metadata
- Authors
- Li, B. T., Ross, D. S., Aisner, D. L., Chaft, J. E., Hsu, M., Kako, S. L., Kris, M. G., Varella-Garcia, M., & Arcila, M. E.
- Affiliations
- The University of Sydney (AU)
- Memorial Sloan Kettering Cancer Center (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Li, Bob T.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 11
- Issue
- 3
- Pages
- 414-419
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC4698879
- OpenAlex
- W2262992387
- Cited by
- 286
- References
- 16
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 23 · 2023: 31 · 2022: 32 · 2021: 42 · 2020: 39 · 2019: 23 · 2018: 23 · 2017: 12 · 2016: 7
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (1RC2 CA148394, P50CA058187, P30 CA046934, P30 CA008748)
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- HER2, HER2 amplification, HER2 mutation, HER2 overexpression, lung adenocarcinoma, HER2 exon 20 insertion, HER2-targeted therapy, molecular subtyping
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Aged, Female, Gene Amplification, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, In Situ Hybridization, Fluorescence, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Genes, erbB-2, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
